Cornerstone Planning Group’s Genmab GMAB Stock Holding History

Cornerstone Planning Group’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.66K	Sell	231 -34	-13%	-$904	﹤0.01%	1013
2026 Q1	$7.29K	Buy	265 +40	+18%	+$1.2K	﹤0.01%	992
2025 Q4	$7.41K	Buy	225 +27	+14%	+$842	﹤0.01%	868
2025 Q3	$5.68K	Buy	198 +101	+104%	+$2.46K	﹤0.01%	921
2025 Q2	$2.14K	Buy	97 +64	+194%	+$1.31K	﹤0.01%	927
2025 Q1	$664	Sell	33 -59	-64%	-$1.24K	﹤0.01%	1220
2024 Q4	$1.91K	Sell	92 -19	-17%	-$417	﹤0.01%	806
2024 Q3	$2.57K	Buy	111 +21	+23%	+$561	﹤0.01%	716
2024 Q2	$2.35K	Buy	90 +63	+233%	+$1.79K	﹤0.01%	726
2024 Q1	$803	Buy	+27	New	+$793	﹤0.01%	829

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cornerstone Planning Group's GMAB Position: Q2 2026 in Review

Cornerstone Planning Group reduced its Genmab (GMAB) stake by 13% in Q2 2026, selling an estimated $904 and leaving 231 shares worth $6.66K. The position accounts for ﹤0.01% of the portfolio, ranked #1013.

Cornerstone Planning Group first reported a position in GMAB in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.41K in Q4 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Cornerstone Planning Group held 231 shares of Genmab worth $6.66K as of Q2 2026.
Cornerstone Planning Group sold 34 Genmab shares in Q2 2026, an estimated $904.
Genmab made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1013 holding.
Cornerstone Planning Group first reported a position in Genmab in Q1 2024 and has held it in 10 quarters since.
Cornerstone Planning Group's Genmab position peaked at $7.41K in Q4 2025.
290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.